Guidance and procedures for implementing tariff adjustments for specialty pharmaceuticals and associated pharmaceutical ingredients
Tariff adjustments can change the landed cost and flow of specialty pharmaceuticals and their ingredients.
Source →The trace
How it reaches your house.
Starting from Cancer and specialty drugs, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Cancer and specialty drugs →Prices easeGeneric Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
Generic and biosimilar drugs are exempt for now under the BIS guidance, so these oncology injectables avoid the tariff shock and gain relative price relief.
88% confidenceCancer and specialty drugs →Prices riseLipid nanoparticle (LNP) lipid components
LNP lipids are associated pharmaceutical ingredients for specialty drugs, so tariffs on specialty pharmaceuticals and ingredients would raise their landed cost.
70% confidenceHovione →Prices rise
Where it lands
What you buy, and what you own.
Goods you buy
Cancer and specialty drugs · Antibiotics
In the MyPRIA app, this is checked against your own holdings.